Introduction
Introduction

Primary infection by human cytomegalovirus (HCMV) is usually mild or asymptomatic and it is effectively controlled by T-cellmediated immune response in healthy individuals
. However, congenital HCMV infection in newborns [2] and viral reactivation in pharmacologically immunosuppressed patients transplanted with solid organs [3] or haematopoietic stem cells (HSCT) [4] are frequently associated with significant morbidity and, eventually, mortality, until the immune system is effectively competent or completely reconstituted [5] . Thus, women in childbearing age and transplant recipients may represent candidate target populations for HCMV active protection. [6] .
T-cell-mediated immune response against immunogenic viral targets is of paramount importance due the potential capacity of epitope-specific cytotoxic T lymphocytes (CTLs) to control viral fitness. The administration of major histocompatibility complex (MHC)-restricted immunodominant synthetic peptides to generate CTL immunity preventing the reactivation of HCMV infection represents a promising approach already tested in clinical trials
Interestingly, vaccination of HSCT donors expressing specific HLA determinants might also be important for the generation of HCMVspecific T cells of potential use in adoptive immunotherapy. In this case, healthy virus carriers might represent an important reservoir of antigen-specific CD4
ϩ and CD8 ϩ T cells. [7] .
Although much emphasis has been placed on the role of MHC class I restricted CD8 ϩ T cells in the recognition of HCMV-infected cells, there is increasing evidence that CD4 ϩ T cells also have a crucial role in the control of HCMV infection
A HCMV pp65 polypeptide promotes the expansion of CD4 [8, 9] . Furthermore, transfer of HCMV-specific CD4 ϩ T cells into HSCT has also been found to promote the expansion of HCMV-specific CD8 ϩ CTLs [10] likely due to the helper function exerted by antigen expanded CD4 ϩ T-cell populations [11] . The concomitant use of MHC class I and II restricted peptides would be highly desirable to achieve effective immune responses [12] . However, limitations inherent in MHC diversity and epitope hierarchies within HLA presentation [13] [14, 15] for each HLA determinant of interest.
Indeed, a large number of immunodominant HLA class I and II restricted HCMV-derived peptides have been identified [16] . However, only a minority of them has been used in clinical procedures due to the necessity of tailoring immunogens according to specific HLA typing [17] .
To [24] . When indicated, absolute numbers of cytokine encoding gene copies were calculated as previously described [22] . 
address these issues, we attempted the identification of highly immunogenic sequences within HCMV pp65 possibly encompassing both class I and II restricted epitopes using a combination of predictive algorithms. Here we report the functional characterization of a highly immunogenic pp65-derived peptide (RQYDPVAALFFFDIDL; hereafter referred as RQY-16mer peptide) capable of inducing class I and II restricted cytotoxic and lymphoproliferative responses across a wide range of HLA specificities.
Materials and methods
Peptide selection, design and synthesis
Generation of EBV transformed cell lines
Cytokine intracellular staining and T-cell phenotype
Cytotoxicity assays
Glutaraldehyde fixation
Immature DCs were fixed as described by Shimonkevitz et al. [27] . [28] , BKV LTag579Ϫ587 [26] , EBV LMP1159Ϫ167 [12] ) and non-latent viruses (Flu M158Ϫ66 [29] ) were also unable to induce cytokine gene expression. Fig. 2 Fig. 2A) . 
A
, this peptide induced significant IFN-␥ gene expression in cells from the two donors (D9 and D10) bearing one or more of these specificities, but its immunogenic activity was barely detectable in the donor (D11) lacking the expression of these alleles (
These findings were supported by cytotoxicity assays performed by using RQY-16mer peptide expanded CTLs from the three representative donors under investigation as effectors and autologous EBV-transformed B cell loaded with specific HLA class I restricted matching peptides as targets. Significant levels of specific lysis at 10:1 E/T ratio (⌬SL10:1) could be observed by pulsing target cells with 9mer-peptides capable of inducing IFN-␥ gene expression (Fig. 2B).
Comparative analysis of CD8 ؉ T-cell re-activation by RQY-16mer and RQY-or QYD-9mers induction
To further characterize the CD8 ϩ T-cell stimulating capacity of
RQY-16mer, multimeric reagents inclusive of HLA-A*0201 or HLA-A*2402 and immunodominant RQY-or QYD-9mers, respectively, were generated. These tools allowed to ex vivo stain sizeable percentages of CD8 ϩ T cells from HCMV-seropositive donors expressing specific HLA alleles (Fig. 2C and F). T cells from the two donors (D9 and D10) were co-cultured with autologous mDCs in the presence of RQY-16mer or RQY-or QYD-9mers peptides. Multimer stainings and specific cytotoxic activities were then evaluated. Predictably, RQY-or QYD-9mers were highly effective in expanding specific CD8 ϩ T cells endowed with cytotoxic capacity (Fig. 2D and G). Most interestingly, RQY-16mer was also effective in expanding CD8
ϩ T cells with similar phenotypic and functional features ( Fig. 2E and H) . (Fig. 3B ) [32] .
Stimulation of both CD4 ϩ and CD8 ϩ T-cell responses by RQY-16mer requires active processing by peptide-pulsed DCs
We hypothesized that RQY-16mer could be fully internalized into DCs, processed through an exogenous pathway and cross © 2008 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd antigenic peptide for 2 weeks and then challenged for 3 hrs in the presence or absence of RQY-16mer peptide. RQY-16mer stimulation of T cells from seronegative donors (n ϭ 2) failed to induce increases in cytokine gene expression exceeding cut-off values (see panels B-E, empty circles). (B-E) Specific RQY-16mer T-cell reactivation as an hallmark of HCMV latency. Numbers of IFN-␥ and TNF-␣ gene transcript copies induced by RQY-16mer stimulation in either CD4
Cytokine production by RQY-16mer specific CD4 ϩ T cells (Table 3B) .
Discussion
